Axial VC

Stately Bio operates in stealth mode and focuses on advancing the understanding of cellular dynamics through its innovative technology. The company has developed patented machine learning methods that allow for the measurement of cell identity, behavior, and maturation through live-cell, label-free imaging. This approach enables researchers to gain insights into cells while maintaining their viability, providing a valuable tool for various applications in biological research and medicine.

AI research assistant for biology.

Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides, which possess antibody-like binding affinity. Utilizing an automated platform that integrates molecular biology and parallel synthetic chemistry, Insamo aims to rapidly identify preclinical candidates with favorable pharmacological properties. This innovative approach enables the potential replacement of traditional injected or infused biologics with more accessible oral formulations, thereby enhancing patient care. The company's automated design, synthesis, and testing processes allow for unprecedented scalability in the discovery of these therapeutic compounds.

Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to create stabilized, solubilized, and catalytically optimized proteins. Using advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach enables the engineering of biological molecules for applications in agriculture and pharmaceuticals, allowing researchers to enhance the effectiveness and durability of proteins beyond their natural capabilities.

Nalu Bio is a biotech company focused on creating cannabinoids through innovative chemical processes rather than traditional plant extraction. This novel approach allows Nalu Bio to produce pure and safe ingredients that are environmentally sustainable, utilizing significantly less land, water, and energy compared to conventional methods. The company's proprietary chemistry platform ensures consistency and quality by generating identical batches of cannabinoids, free from contaminants such as pesticides and THC. Targeting both consumer and pharmaceutical markets, Nalu Bio aims to disrupt the cannabinoid industry by providing a reliable source of high-quality ingredients that meet the growing demand for safe and effective products.

Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications.

Network Bio operates a clinical and molecular data library focused on facilitating precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, allowing researchers to analyze patterns and correlations. This analysis can lead to the development of new treatments and diagnostic tools, thereby advancing medical research and improving patient outcomes.

Think Bioscience is focused on advancing synthetic biology to enhance the design and assembly of improved medicines. The company utilizes a unique technology that encodes complex molecular objectives into microbial hosts, facilitating the identification, construction, and evolution of small molecules. This innovative approach allows medical researchers to leverage microbes in the drug discovery process, potentially leading to more effective therapeutic solutions. Through its efforts, Think Bioscience aims to transform how medicines are developed and contribute to the future of healthcare.

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biological systems through the synthesis and delivery of large DNA sequences. By innovating in the field of genetic engineering, Replay seeks to redefine the possibilities of genome manipulation and its applications in various medical and therapeutic contexts. Their work aims to facilitate breakthroughs in how genes can be utilized to treat diseases and enhance biological functions, positioning them at the forefront of the evolving landscape of genetic technology.

CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.

Omica is Latin America's Biomedical Data Hub. We aggregate high quality datasets for Life Science R&D. Our platform consists of an AI-enhanced EMR system linked to a multi-omics biobank.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Enable Medicine is a biotechnology company based in Menlo Park, California, founded in 2019 by Aaron Mayer and Sunil Bodapati. The company specializes in spatial biology data, offering a cloud-based platform that facilitates the generation, management, and analysis of various biological image formats. Enable Medicine's platform provides end-to-end services, including custom panel development and advanced imaging technology, which support researchers, drug developers, and physicians in creating detailed cellular maps. This comprehensive approach enables users to extract valuable insights from diverse sample types, thereby accelerating the drug discovery process and reducing associated costs.

Zeit Medical provides therapy for neurological injuries by identifying signature patterns in EEG and enables physicians to diagnose and treat with precision. The company was founded in 20202019 by Urs Naber and Orestis Vardoulis.

Options MD is a telemedicine platform focused on delivering personalized care for individuals experiencing severe and treatment-resistant mental illnesses. The platform utilizes artificial intelligence to match patients with innovative depression care options provided by psychiatric experts. By streamlining the referral process to in-house specialists, Options MD enables patients to access appropriate medical care more efficiently, aiming to improve their treatment outcomes.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Powered by genomics, skin microbiome science, and machine learning, Parallel is an end-to-end next-generation skin health company providing derm telehealth, cutting-edge skin microbiome diagnostics, precision microbiome skincare, and personalized Rx